Design Therapeutics

Historical price data

Design Therapeutics is a clinical-stage biotech focused on developing disease-modifying therapies for severe genetic disorders driven by nucleotide repeat expansions. Its core innovation is the GeneTAC™ platform, which creates bifunctional small molecules that can precisely upregulate or downregulate disease-causing genes without altering DNA. The company's strategy targets monogenic diseases with high unmet need, advancing a pipeline led by DT-216P2 for Friedreich's ataxia, now in Phase 1/2 trials, alongside preclinical programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type 1.

The GeneTAC™ (Gene Targeted Chimera) platform engineers bifunctional small molecules that bind to disease-causing nucleotide repeat expansions and recruit cellular machinery to precisely upregulate or downregulate gene expression without altering DNA.

In Friedreich's ataxia, Design competes with protein replacement (Larimar) and gene therapies, differentiating by aiming to restore endogenous gene expression. For its broader platform, it competes with RNA-targeting modalities (antisense, siRNA) and gene editing, with its key claimed advantages being systemic delivery via small molecules and non-permanent gene modulation.